Journal 33.07: Treatment of Restless Legs Syndrome: Evidence-Based Review and Implications for Clinical Practice

Be the first to review this product

Availability: In stock

$50.00

Quick Overview

Member price: $0.00


CME Credits: 1

Journal 33.07: Treatment of Restless Legs Syndrome: Evidence-Based Review and Implications for Clinical Practice

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

Details

The objective of the current review was to update the previous evidence-based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise, new data enable the modification of the level of efficacy for rotigotine from likely efficacious to efficacious. This course will take approximately 1 hour to complete.

Faculty-  Dr. Juliane Winkelman,  Dr. Richard P. Allen, Dr. Birgit Hogl, Dr.Yuichi Inoue, Dr. Wolfgang Oertel, Dr. Aaro V. Salminen, Dr. John W. Winkelman, Dr. Claudia Trenkwalder, Dr. Christina Sampaio

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.